Application of speCtraL Computed tomogrAphy to impRove specIficity of Cardiac compuTed tomographY

NCT03139006 | Unknown FDA Device

• 1 other identifier: NL55917.041.16
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Coronary computed tomography angiography (CCTA) and, if indicated, invasively measured fractional flow reserve (FFR) is currently used for ruling out significant coronary artery disease. FFRCT is a novel non-invasive technique in which FFR is derived from CT images, however this method is currently, just like CCTA, lacking specificity. Spectral Detector CT (SDCT) is a novel technique whereby a spectrum of monoenergetic images at different kiloelectron Volt (keV) values (40 to 200 keV) can be reconstructed. By using these monoenergetic images, a decrease in blooming and beam-hardening artifacts could be achieved. In addition, SDCT offers the opportunity to assess myocardial iodine distribution and quantification. When combining these factors, we hypothesize more accurate information will be available about the coronary anatomy, degree of stenosis and FFRCT and thereby contribute to a more accurate way for the detection of hemodynamic significant stenosis. Therefore, the aim of this study is to assess the accuracy of SDCT as a non-invasive way for the detection of hemodynamically significant coronary artery stenosis. Objective: The overall objective of this project is to assess the accuracy of SDCT for the detection of flow limiting stenosis in the coronary arteries using invasive FFR as the standard of reference. Whereby different sub-aims (e.g. improvement of FFRCT) are made to answer the overall objective. The secondary objective is to determine the decrease of calcium blooming of calcifications and beam-hardening artifacts and the improvement of myocardial blood volume quantification on SDCT in comparison with conventional CT.

Conditions

Coronary Stenosis; Myocardial Ischemia; Cardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

• Flow limiting stenosis in the coronary arteries defined by invasive fractional flow reserve (FFR)

  An invasive FFR \<0.8 indicates a flow limiting stenosis

  within 30 days

Interventions

Dual-layer spectral detector CT DEVICE

A dual energy CT approach

Also known as: SDCT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Participants ≥18 years of age with suspected or known stable angina with pre-test likelihood of 50-85% for obstructive coronary disease (Eur Heart J 2013 guidelines on stable CAD) and who are referred for clinical invasive FFR.

You may qualify if:

• ≥18 years old;
• Suspected or known stable angina with pre-test likelihood of 50-85% for obstructive coronary disease, using the method recommended by the European Society of Cardiology 2013 Guidelines on the management of stable coronary artery disease (Eur Heart J 2013);
• Referred for invasive testing with fractional flow reserve;
• Willing and able to give informed consent. The consent procedures, as set by the Institutional Review Board (IRB) will be followed.

You may not qualify if:

• Subjects with suspected or known stable angina with pre-test likelihood of 0-50% using the method recommended by the European Society of Cardiology 2013 Guidelines on the management of stable coronary artery disease (Eur Heart J 2013 \[24\]);
• Subjects who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent or tolerate the coronary CTA examination;
• Subjects with (severe) renal insufficiency, indicated as glomerular filtration rate (GFR) \<60 ml/min;
• Subjects with unknown GFR or obtained \>3 months before the planned scan;
• Contraindication or allergy to intravenous contrast agent(s);
• Subjects who participate in an other study with radiation which is estimated to be in risk category III (ICRP 62);
• Subjects who are pregnant;
• Subjects with contraindications to cardiac CT and/or S\&S protocol, intravenous contrast, intravenous adenosine, betablockers or nitroglycerine.

Sponsors & Collaborators

• UMC Utrecht: lead

Study Sites (1)

University Medical Center UtrechtU

Utrecht, 3508GA, Netherlands

RECRUITING

Related Publications (1)

• van Hamersvelt RW, Isgum I, de Jong PA, Cramer MJM, Leenders GEH, Willemink MJ, Voskuil M, Leiner T. Application of speCtraL computed tomogrAphy to impRove specIficity of cardiac compuTed tomographY (CLARITY study): rationale and design. BMJ Open. 2019 Mar 1;9(3):e025793. doi: 10.1136/bmjopen-2018-025793.

  PMID: 30826767 DERIVED

MeSH Terms

Conditions

Coronary Stenosis; Myocardial Ischemia; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Coronary Disease; Heart Diseases; Vascular Diseases

Study Officials

• Tim Leiner, MD, PhD

  UMC Utrecht

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Robbert van Hamersvelt, MD

CONTACT

+31887550441; R.W.vanHamersvelt-3@umcutrecht.nl

Tim Leiner, MD, PhD

CONTACT

+31887556687; T.Leiner@umcutrecht.nl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr.

Study Record Dates

• First Submitted: May 1, 2017
• First Posted: May 3, 2017
• Study Start: March 29, 2017
• Primary Completion: March 29, 2021
• Study Completion: September 1, 2021
• Last Updated: October 17, 2018

Record last verified: 2018-10

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)